Search Results Search Sort by RelevanceMost Recent Case and Commentary Dec 2018 When Should Iatrogenic Polypharmacy Be Considered a Disease? Christine Wieseler, PhD When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical. AMA J Ethics. 2018;20(12):E1133-1138. doi: 10.1001/amajethics.2018.1133. Case and Commentary Dec 2005 Media Attention to End-of-Life Cases, Commentary 1 Ware G. Kuschner, MD Virtual Mentor. 2005;7(12):775-779. doi: 10.1001/virtualmentor.2005.7.12.ccas1-0512. Case and Commentary Dec 2005 Media Attention to End-of-Life Cases, Commentary 2 John J. Paris, SJ, PhD Virtual Mentor. 2005;7(12):779-782. doi: 10.1001/virtualmentor.2005.7.12.ccas1-0512. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Case and Commentary Dec 2018 When Should Iatrogenic Polypharmacy Be Considered a Disease? Christine Wieseler, PhD When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical. AMA J Ethics. 2018;20(12):E1133-1138. doi: 10.1001/amajethics.2018.1133.
Case and Commentary Dec 2005 Media Attention to End-of-Life Cases, Commentary 1 Ware G. Kuschner, MD Virtual Mentor. 2005;7(12):775-779. doi: 10.1001/virtualmentor.2005.7.12.ccas1-0512.
Case and Commentary Dec 2005 Media Attention to End-of-Life Cases, Commentary 2 John J. Paris, SJ, PhD Virtual Mentor. 2005;7(12):779-782. doi: 10.1001/virtualmentor.2005.7.12.ccas1-0512.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.